Verrix, a San Clemente, CA-based medical device company developing solutions for rapid and accurate sterilization confirmation, completed an initial close on a Series B funding round for $8m.
This will bring total funds raised to $17.5m.
The company intends to use the funds to finalize development, regulatory submission, and commercialization of its EVA™ Biological Indicator (BI) System.
Founded as a standalone company in 2013 and led by Cameron Rouns, CEO, Verrix is a San Clemente, Calif.-based medical device company that is using advanced technologies to protect patients from healthcare-associated infections. The foundational sterility assurance technology, originally discovered at NASA’s Jet Propulsion Laboratory, integrates optical physics, chemistry spectroscopy, and molecular biology.
The first BI system developed based on the company’s technology advances is expected to be introduced in 2019.
FinSMEs
27/11/2018